전승혁 (분당서울대학교병원)님 | 한빛사연구자 > 한빛사

분당서울대학교병원

최종업데이트 2024.05.16.

Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinoma
- Cell Rep. Med., September 16 | https://doi.org/10.1016/j.xcrm.2025.102360
- 2025-09
- 생명과학
- 한빛사논문
Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancer
- Clin. Cancer Res., Aug 20 2025, | https://doi.org/10.1158/1078-0432.CCR-24-3283
- 2025-08
- 의약학
- 한빛사논문
Co-blockade of TGFβ and PD-1 reinvigorates glioblastoma-infiltrating CD8+ T cells that characteristically upregulate TGFβR expression
- Clin. Cancer Res., Jun 03 2025, | https://doi.org/10.1158/1078-0432.CCR-24-2184
- 2025-06
- 의약학
- 한빛사논문
Anti-4-1BB×PD-L1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD-1 Blockade
- Clin. Cancer Res., May 14 2024, | https://doi.org/10.1158/1078-0432.CCR-23-2864
- 2024-05
- 의약학
- 한빛사논문
CEACAM1 marks highly suppressive intratumoral regulatory T cells for targeted depletion therapy
- Clin. Cancer Res., FEBRUARY 22 2023;CCR-22-1843 | https://doi.org/10.1158/1078-0432.CCR-22-1843
- 2023-02
- 의약학
- 한빛사논문

연구자 ID

저자논문